Summary Financials People Signals & News. Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. About Jasper Therapeutics. Search Crunchbase. The … Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, today announced they have entered into a definitive business combination agreement. Jasper. About Jasper Therapeutics. Stable Road Adjourns Stockholder Meeting to May 13 for Deadline Extension Vote. The company’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell … Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of … Advanced Search. Financing. The … Jasper Therapeutics. Organization. About Jasper Therapeutics. Biotech firm, Jasper Therapeutics Inc, is planning to go public via a reverse SPAC merger deal with Amplitude Healthcare Acquisition Corp (NASDAQ: AMHC) in a $100 million deal. Abingworth LLP and Qiming Venture Partners USA served as lead investors, with … The … Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, today announced they have entered into a definitive business combination agreement. Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. About Arch Therapeutics, Inc.Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. Bill Lis, Jasper Therapeutics. Jasper Therapeutics and the National … Connect to CRM . Jasper Therapeutics, Inc., a new biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell transplants and gene therapies, today announced the launch of the company with a $35 million total Series A financing. The deal also comes with a … About. JSP191 is a targeted, first-in-class humanized monoclonal antibody in clinical development as a conditioning agent to clear hematopoietic stem cells from bone marrow prior to transplant. The trial is evaluating JSP191 as a conditioning agent to enable stem cell … Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of … Resources . Pricing. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the launch of a Phase 1/2 clinical trial to evaluate JSP191, Jasper’s first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for sickle cell disease (SCD). Resources. Thursday’s winner is Jasper Therapeutics, joining forces with Amplitude Healthcare Acquisition Corp. in a $100 million reverse-merger, Jasper announced. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer … Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the launch of a Phase 1/2 clinical trial to evaluate JSP191, Jasper’s first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for sickle cell disease (SCD). Products. About Jasper Therapeutics Jasper Therapeutics is a biotechnology company focused on hematopoietic cell transplant therapies. Try Pro free Solutions. Save . Overall, GuruFocus ranks Intellia Therapeutics's profitability as poor. Upon … Upon … In this newly created role, Dr. Heller will lead the Company’s clinical and research functions and oversee clinical development, clinical strategy and operations, medical … Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic agents that expand the application of curative hematopoietic stem cell … Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the appointment of Kevin N. Heller, M.D., as Executive Vice President, Research & Development. Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman and … NEWS CENTER; CAREERS; JSP191. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced clinical data from its ongoing multicenter Phase 1 clinical trial of JSP191, a first-in-class anti-CD117 monoclonal antibody, in patients with severe combined immune deficiency (SCID). Jasper Therapeutics is a biotechnology company focused … Sign up to our free newsletter Stay … Jasper Therapeutics has raised an additional $14.1 million to finance the development of its investigational conditioning therapy, JSP191, as a safer and more effective treatment to prepare patients for stem cell transplant.. Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation . Log In. Plum Acquisition I Shares & Warrants May Now Trade Separately. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced the launch of a Phase 1/2 clinical trial to evaluate JSP191, Jasper… Its operating margin of -235.51% in the middle range of the companies in Biotechnology industry. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:20 p.m. Eastern Time. Coinbase Direct Listing Steadies Crypto Industry: Report. The company’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplant. Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic. Thursday’s winner is Jasper Therapeutics, joining forces with Amplitude Healthcare Acquisition Corp. in a $100 million reverse-merger, Jasper announced. Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced clinical data from its … Biotech firm, Jasper Therapeutics Inc, is planning to go public via a reverse SPAC merger deal with Amplitude Healthcare Acquisition Corp (NASDAQ: AMHC) in … Intellia Therapeutics has been profitable 0 years over the past 10 years. The investment, led by Roche Venture Fund and sponsored by other investors, increases the company financing to more than $50 million, the company stated in a press … During the past 12 months, the company had revenues of $58 million and loss of $2.4 a share. Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. May 6, 2021 10:32 AM EDT Updated 02:27 PM. Biotech firm, Jasper Therapeutics Inc, is planning to go public via a reverse SPAC merger deal with Amplitude Healthcare Acquisition Corp (NASDAQ: AMHC) in … The deal also comes with a … About Jasper Therapeutics. Article. Search Trending Posts. Horizon Acquisition and Sportradar Extend Their Negotiations: Report . Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, today announced they have entered into a definitive business combination agreement. Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease . The Art of the SPAC: From Sublime to Ridiculous.